Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMR) and their connected persons, specifically regarding awards under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific equity transactions rather than a financial performance report.
Material Changes and Transactions
On February 12, 2014, awards were made under the Performance Share Plan to the following individuals:
- Mr. P. Thomson (PDMR) and Mrs. K. Thomson (Connected Person): Received 1,946 Ordinary Shares.
- Dr. M. Slaoui (Executive Director) and Mrs. K. Slaoui (Connected Person): Received 2,030 American Depositary Shares (ADS).
The awards were valued based on the following closing prices on February 12, 2014:
- Ordinary Share: £16.505
- ADS: US$54.81
Vesting of these awards is subject to meeting performance criteria over a three-year period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary risk noted is the conditional nature of the awards, which depend on future performance criteria.
Investor Verification Checklist
- Verify the vesting schedule and specific performance criteria attached to the February 12, 2014 awards.
- Confirm the total number of shares outstanding following these specific PDMR transactions.
- Review the full GlaxoSmithKline 2009 Performance Share Plan document for detailed terms.